The 3 Star Study will research and test whether an investigational vaccine can affect Alzheimer’s disease-related brain changes in participants with Down Syndrome.The 3 Star Study is designed for individuals who have Down Syndrome, are 25-45 years of age, do not have any other serious illness, and have a caregiver or informant who can answer questions about them.
T2 is designed to determine if troriluzole can protect, slow down, or potentially improve memory and thinking problems that increase as Alzheimer’s disease progresses.
The Discover Study is a randomized, double-blind, placebo controlled study. Participants will be treated with a low, middle, or high dose of Posiphen, or a placebo (a capsule that looks like the study drug but does not contain active ingredients).
PEACE-AD is a multicenter, randomized, placebo-controlled study evaluating the efficacy and safety of the Prazosin drug.
SALAD is a Phase 1b, 12-month, randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of salsalate in patients with mild to moderate Alzheimer’s disease.
NEAT is a Phase 2, proof of concept, double-blind, randomized, placebo-controlled adaptive design trial of Nicotinamide in MCI due to AD and Mild AD Dementia.
The EXERT study is a national, 18-month long, clinical trial to test whether physical exercise can slow the progression of mild memory loss and/or mild cognitive impairment in older adults between the ages of 65-89.
NOBLE is a clinical study to evaluate an investigational drug for patients with mild to moderate Alzheimer’s disease. The investigational drug may work by protecting brain cells, which could result in improved memory. The study will determine whether the drug is efficacious.
A Phase II clinical study of Resveratrol (RES) designed to evaluate the safety, tolerability and effectiveness of Resveratrol on cerebrospinal fluid and other biomarkers for the treatment of Alzheimer’s disease.
Evaluate three methods of performing home-based assessments in an Alzheimer’s disease prevention trial.
Ceregene’s CERE-110 gene therapy product designed to deliver nerve growth factor (NGF) to the brain for the treatment of Alzheimer’s disease is currently underway.
Determine whether imaging of the brain every six months can help predict the onset of Alzheimer’s disease, and monitor the progression of the disease as well.
Further examination of the safety, effectiveness and tolerability of IVIg in mild to moderate Alzheimer’s Disease patients.
A randomized, double-blind, placebo-controlled trial of the effects of Docosahexaenoic Acid (DHA) in slowing the progression of Alzheimer’s disease.
Determine whether chronic valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer’s disease who have not experienced agitation and psychosis in their illness.
The experimental drug in this study may block a critical pathway in Alzheimer’s disease that causes damage to the nerve cells in the brain.
A multicenter, double-blind, placebo-controlled therapeutic trial to determine whether natural huperzine A improves cognitive function in Alzheimer’s disease.
